FAS and systemic lupus erythematosus: Successful development of the S1P analog FTY720 and its use as a drug to treat multiple sclerosis (69) shows that it is possible to target S1P signaling in humans and, therefore, that S1P antagonists would be an attractive therapeutic option for preventing CD95-mediated transmigration of Th17 cells in SLE patients (Figure 1).